The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent THC or CBD use. Other pharmacodynamic effects of oral THC or CBD will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
22
University of California, Los Angeles
Los Angeles, California, United States
Ratings of subjective drug effects
Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).
Time frame: 6 hours
Concentration of THC, CBD and metabolites in whole blood
Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH as measured in ng/ml
Time frame: 6 hours
Behavioral task performance as assessed by the DRUID App Score
Composite score on the DRUID App, a measure of behavioral task performance (range 0-100) where lower scores indicate better performance
Time frame: 6 hours
Concentration of THC in oral fluid
Liquid chromatography-tandem mass spectrometry
Time frame: 6 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral THC (20 mg) + CBD (20 mg)